Solasia Pharma KK
TSE:4597
Intrinsic Value
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. [ Read More ]
The intrinsic value of one Solasia Pharma KK stock under the Base Case scenario is 37.13 JPY. Compared to the current market price of 26 JPY, Solasia Pharma KK is Undervalued by 30%.
Valuation Backtest
Solasia Pharma KK
Run backtest to discover the historical profit from buying and selling Solasia Pharma KK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Solasia Pharma KK
Current Assets | 976m |
Cash & Short-Term Investments | 728m |
Receivables | 67m |
Other Current Assets | 181m |
Non-Current Assets | 1.3B |
Long-Term Investments | 6m |
PP&E | 81m |
Intangibles | 1.1B |
Other Non-Current Assets | 49m |
Current Liabilities | 293m |
Accounts Payable | 213m |
Other Current Liabilities | 80m |
Non-Current Liabilities | 61m |
Long-Term Debt | 27m |
Other Non-Current Liabilities | 34m |
Earnings Waterfall
Solasia Pharma KK
Revenue
|
617m
JPY
|
Cost of Revenue
|
-280m
JPY
|
Gross Profit
|
337m
JPY
|
Operating Expenses
|
-1.5B
JPY
|
Operating Income
|
-1.1B
JPY
|
Other Expenses
|
27m
JPY
|
Net Income
|
-1.1B
JPY
|
Free Cash Flow Analysis
Solasia Pharma KK
Profitability Score
Profitability Due Diligence
Solasia Pharma KK's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Solasia Pharma KK's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Solasia Pharma KK's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Score
Solasia Pharma KK's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Solasia Pharma KK
According to Wall Street analysts, the average 1-year price target for Solasia Pharma KK is 86.7 JPY with a low forecast of 85.85 JPY and a high forecast of 89.25 JPY.
Shareholder Return
Price
Solasia Pharma KK
Average Annual Return | -25.92% |
Standard Deviation of Annual Returns | 23.74% |
Max Drawdown | -89% |
Market Capitalization | 4.5B JPY |
Shares Outstanding | 181 693 090 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 77 full-time employees. The company went IPO on 2017-03-24. is a Japan-based pharmaceutical company. The firm is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. The company focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The firm's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).
Contact
IPO
Employees
Officers
The intrinsic value of one Solasia Pharma KK stock under the Base Case scenario is 37.13 JPY.
Compared to the current market price of 26 JPY, Solasia Pharma KK is Undervalued by 30%.